🚨 #ESMO26 | #Podium2Screen — LITESPARK-012 @OncoAlert A useful reminder in advanced #RCC: Adding more active drugs does not necessarily create a better first-line regimen. @DrChoueiri presents phase III LITESPARK-012, evaluating whether adding either belzutifan or the CTLA-4 antibody quavonlimab to pembrolizumab + lenvatinib could improve outcomes. 📊 n=1,688 ➡️ No improvement in PFS ➡️ No improvement in OS ➡️ No improvement in ORR ➡️ Higher treatment discontinuation in the triplet arms 🎯 Why this matters: negative trials can be highly informative. They tell us that simply layering another mechanistically attractive agent onto an effective backbone is not enough. Biology, sequencing, toxicity and patient selection still matter. For me, the message is clear: pembrolizumab + lenvatinib remains an established 1L standard — and future intensification needs a stronger biological rationale, not just another drug. Excellent discussion by @DrChoueiri with @tompowles1 @MVossMD @ERPlimackMD @HowardGurney @brian_rini Pinging @DrDanielHeng @TiansterZhang @HHammersMD @AlbigesL @montypal @apolo_andrea @crisbergerot @neerajaiims @DrYukselUrun @nataliagandur #OncoAlert #ESMO26 #KidneyCancer #ccRCC #Immunotherapy #Belzutifan #GUOncology